Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

ination with Capecitabine in Patients with Advanced Breast Cancer.
  • Patricia Gomez, M.D., Breast Cancer Center, Vall d'Hebron University Hospital, Barcelona, Spain
  • Abstract 1083, General Poster Session, Breast Cancer Track
  • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

"With more than 70 investigator and company sponsored studies being presented at ASCO, we look forward to continuing our work with investigators to understand how Nexavar may fit into other areas of the therapeutic landscape, particularly with respect to how biomarkers status may guide selection of therapy, which is a step toward personalized medicine," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.  

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by other companies, international study groups, government agencies a
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 regulated information -- UCB ... and development pipeline with positive topline results from ... . This study was designed to evaluate the efficacy ... 200 mg/day, without titration) compared to placebo, as ... partial-onset seizures, not fully controlled despite treatment with ...
(Date:7/23/2014)... , July 23, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... Limited ("Cordlife"), a multi-product healthcare company catering to the mother and ... in assisting patients across the PRC, Singapore , ... India , the Philippines ...
(Date:7/23/2014)... July 23, 2014 Adult stem ... therapies are biological, but not magical. However, ... to treat them as if they were magical. ... unsanctioned studies that constitute “stem cell tourism,” are ... approach to developing new regenerative medicine therapies. In ...
(Date:7/22/2014)... a phylum so full of mean little creatures, the yellow-colored ... cruelty -- at least to crickets. Native to the southeastern ... predatory sort of parasite. It swoops onto the back of ... leaves its wicked brood to invade, kill and consume the ... be possible without the fly,s ability to find a cricket ...
Breaking Biology Technology:Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4
... Md., Aug. 14 Martek Biosciences,Corporation announced that it ... fiscal 2007 on September 5, 2007, at approximately 4:00 ... p.m. EDT Martek,will hold a conference call to discuss ... investors. The call is expected to be approximately one,hour ...
... 14 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,(TSX: DDD; OTCBB: DRUG; BBSE: DRP) ... 2007. Highlights of the Second Quarter, 2007, - ... the same period of 2006, and ... quarter 2007;, - Gross profit and gross ...
... 15 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated ... AG (Wedel, Germany), its European partner,for the ... has recruited the 40th and final patient ...
Cached Biology Technology:Martek to Announce Third Quarter 2007 Results on September 5, 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 3ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 2ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 3ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB 4
(Date:7/22/2014)... UT Arlington computer science and engineering professor with an ... three-year National Science Foundation grant worth more than $600,000 ... the fruit fly., Heng Huang, an associate professor, will ... the UT Arlington Computer Science and Engineering department. Scientists ... because a large number of genes involved in fruit ...
(Date:7/22/2014)... be good for the average steak, but it seems ... to survive Alaska,s winter cold. , "Alaska wood frogs ... steak does in your freezer and the frog comes ... than the steak," said Don Larson, University of Alaska ... paper demonstrating that freeze tolerance in Alaska wood frogs ...
(Date:7/22/2014)... Researchers from the USC Schaeffer Center for Health ... governing antipsychotic drugs with increased incarceration rates for ... scrutiny over whether cutbacks in mental health actually ... account. , Some health plans require an extra ... ordered for patients. This step called prior ...
Breaking Biology News(10 mins):UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2Alaska frogs reach record lows in extreme temperature survival 2Alaska frogs reach record lows in extreme temperature survival 3Are state Medicaid policies sentencing people with mental illnesses to prison? 2
... F. Harrington Professor Emeritus at the University of Delaware, ... Heck, 79, was honored alongside fellow researchers Akira Suzuki, ... Negishi, 75, of Purdue University, "for palladium-catalyzed cross couplings ... award. The Nobel Prize in Chemistry was announced ...
... National Science Foundation (NSF) grant to upgrade and expand ... Solar Array (OVSA) http://www.ovsa.njit.edu/ has been ... to help scientists better understand the nature of solar ... "Space weather incidents such as coronal mass ...
... State University finds that fish located near coal-fired power plants ... further away. The surprising finding appears to be linked to ... which unfortunately poses problems of its own. "We found ... from a coal-fired power plant had mercury levels more than ...
Cached Biology News:UD Professor Emeritus wins Nobel Prize in Chemistry 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 3Study: Fish near coal-fired power plants have lower levels of mercury 2
... Recognizes Nabeta2. The epitope ... present in any other known ... expected to work on human ... highly conserved (17/19 residues). Reactivity ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
... for DNA isolation. Designed to ... 96 well plate adapters from Mo ... entire plate length (max capacity is ... used for soil, microorganisms, animal tissue, ...
Biology Products: